Tumor Biology

, Volume 35, Issue 12, pp 12757–12763 | Cite as

Elevated microRNA-185 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in clear cell renal cell carcinoma

  • Hai-Xia Yuan
  • Jian-Ping Zhang
  • Wen-Tao Kong
  • Yu-Jun Liu
  • Zong-Ming Lin
  • Wen-Ping Wang
  • Jian-Ming Guo
Research Article


MicroRNAs (miRNAs) are involved in a number of biological processes, including tumor biology. Previous studies have demonstrated that miRNA-185 regulates signaling downstream of vascular endothelial growth factor receptor 2 (VEGFR-2) and, consequently, angiogenesis. The aim of this study was to analyze the potential relationship between miRNA-185, VEGFR-2, and angiogenesis in samples from renal cell carcinoma (RCC) patients. Tumor tissue was obtained from 82 patients. The miRNA-185 and VEGFR-2 gene expression levels were analyzed by PCR, and the protein concentrations of VEGFR-2 were detected by ELISA. Angiogenesis, visualized by the endothelial cell marker CD34 combined with caldesmon, was assessed by immunohistochemistry and the microvessel density (MVD) technique. In situ hybridization was performed for miRNA-185. Tumors were classified as low or high miRNA-185-expressing using the median as the cutoff. The median gene expression levels of VEGFR-2 were significantly lower in the tumors expressing low levels of miRNA-185, 0.31 (95 % CI, 0.25–0.37), compared to those expressing high levels of miRNA-185, 0.47 (95 % CI, 0.27–0.59), p = 0.02. A positive association was certified with VEGFR-2 protein levels, p = 0.06. The median MVD was significantly lower in the tumors expressing low levels of miRNA-185, 6.8 (95 % CI, 6.33–7.67), compared to those expressing high levels, 8.0 (95 % CI, 6.33-9.00), p < 0.01. miRNA-185 was detected in endothelial cells by in situ hybridization detection. The results suggest that high levels of miRNA-185 in RCC are associated with high VEGFR-2 mRNA and protein levels and a higher density of microvessels. However, further investigation should be performed to analyze the prognostic value of miRNA-185 in RCC.


MicroRNAs Microvessel density Vascular endothelial growth factor receptor 2 Prognosis Renal cell carcinoma 



Special thanks to the faculty of the Department of Pathology, Zhongshan Hospital, Fudan University.

Conflicts of interest



  1. 1.
    Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI, et al. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int. 2010;60:1–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Montironi R, Santinelli A, Pomante R, Mazzucchelli R, Colanzi P, Filho AL, et al. Morphometric index of adult renal cell carcinoma. Comparison with the Fuhrman grading system. Virchows Arch. 2000;437(1):82–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Eklund L, Bry M, Alitalo K. Mouse models for studying angiogenesis and lymph-angiogenesis in cancer. Mol Oncol. 2013;7(2):259–82.PubMedCrossRefGoogle Scholar
  4. 4.
    Chekhonin VP, Shein SA, Korchagina AA, Gurina OI. VEGF in neoplastic angiogenesis. Vestn Ross Akad Med Nauk. 2012;2:23–33.PubMedGoogle Scholar
  5. 5.
    Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2012;2(3):a006486.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol. 2014;24(16):R762–R77.PubMedCrossRefGoogle Scholar
  7. 7.
    Suzuki H, Maruyama R, Yamamoto E, Kai M. Epigenetic alteration and microRNA dysregulation in cancer. Front Genet. 2013;4:258.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Hoffman AM, Cairns P. Epigenetics of kidney cancer and bladder cancer. Epigenomics. 2011;3(1):19–34.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Li W, Liu M, Feng Y, Xu YF, Huang YF, Che JP, et al. Downregulated miR-646 in clear cell renal carcinoma correlated with tumour metastasis by targeting the nin one binding protein (NOB1). Br J Cancer. 2014. doi: 10.1038/bjc.2014.382.Google Scholar
  10. 10.
    McCormick RI, Blick C, Ragoussis J, Schoedel J, Mole DR, Young AC, et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer. 2013;108(5):1133–42.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Zhang Z, Tang H, Wang Z, Zhang B, Liu W, Lu H, et al. MiR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma. Mol Cancer. 2011;10:124.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett. 2009;285(2):116–26.PubMedCrossRefGoogle Scholar
  13. 13.
    Cheng CJ, Slack FJ. The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer J. 2012;18(3):232–7.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Ho JJ, Metcalf JL, Yan MS, Turgeon PJ, Wang JJ, Chalsev M, et al. Functional importance of Dicer protein in the adaptive cellular response to hypoxia. J Biol Chem. 2012;287(34):29003–20.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Ficarra V, Galfano A, Mancini M, Martignoni G, Artibani W. TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol. 2007;8(6):554–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Hansen TF, Spindler KL, Lorentzen KA, Olsen DA, Andersen RF, Lindebjerg J, et al. Quantitative analysis of vascular endothelial growth factor receptors 1 and 2 in colorectal cancer. Mol Med Rep. 2009;2(5):787–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Vartanian RK, Weidner N. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason’s score, microvessel density, and epithelial cell proliferation. Lab Investig. 1995;73(6):844–50.PubMedGoogle Scholar
  18. 18.
    Leal MF, Belangero PS, Cohen C, Figueiredo EA, Loyola LC, Pochini AC, et al. Identification of suitable reference genes for gene expression studies of shoulder instability. PLoS ONE. 2014;9(8):e105002.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Kriegel AJ, Liang M. MicroRNA in situ hybridization for formalin fixed kidney tissues. J Vis Exp. 2013. doi: 10.3791/50785. 81.PubMedGoogle Scholar
  20. 20.
    Plummer PN, Freeman R, Taft RJ, Vider J, Sax M, Umer BA, et al. MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells. Cancer Res. 2013;73(1):341–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Imam JS, Buddavarapu K, Lee-Chang JS, Ganapathy S, Camosy C, Chen Y, et al. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene. 2010;29(35):4971–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Müller S, Nowak K. Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. Biomed Res Int. 2014;2014:948408.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Sharma SG, Aggarwal N, Gupta SD, Singh MK, Gupta R, Dinda AK. Angiogenesis in renal cell carcinoma: correlation of microvessel density and microvessel area with other prognostic factors. Int Urol Nephrol. 2011;43(1):125–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S, et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A. 2013;110(24):9845–50.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Hai-Xia Yuan
    • 1
  • Jian-Ping Zhang
    • 2
  • Wen-Tao Kong
    • 2
  • Yu-Jun Liu
    • 2
  • Zong-Ming Lin
    • 2
  • Wen-Ping Wang
    • 1
  • Jian-Ming Guo
    • 2
  1. 1.Department of Ultrasound, Zhongshan HospitalFudan UniversityShanghaiPeople’s Republic of China
  2. 2.Department of Urology, Zhongshan HospitalFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations